EliseAI invests in Andreessen Horowitz
Funding Provisional 95% confidence first seen
EliseAI (Elise A.I. Technologies Corp.) raised $350 million in a funding round that was led/co-led by Andreessen Horowitz (a16z) alongside Bessemer Venture Partners. The round valued the company at $4 billion, with participation from Ontario Teachers’ Pension Plan and other existing investors. The funding is reported to be used for product development and expanding engineering, deployment, and sales teams, including plans for additional engineering capacity, which underscores investors’ confidence in EliseAI’s AI automation platforms for real estate and healthcare.
The deal
EliseAI $350 million Late stage · announced 29 Sep 2026
Investors Andreessen Horowitz Bessemer Venture Partners Ontario Teachers’ Pension Plan Bessemer
Deal terms as reported in the coverage below.
Decision brief
- What changed
- EliseAI raised $350 million in a funding round led by Andreessen Horowitz and Bessemer, at a reported $4 billion valuation. The company said it will use the capital to expand its AI work-automation suite for real-estate and healthcare customers and hire additional engineers, deployment staff, and salespeople.
- Why it matters
- This signals that well-known investors are backing further scale-up of AI workflow automation in two operationally intensive industries, which may increase competitive pressure on vendors and operators in real estate and healthcare. For business leaders evaluating automation partners, the funding suggests EliseAI may have more capacity to build product, support deployments, and expand go-to-market coverage, which can affect vendor selection and partnership timing.
- Evidence
- The provided coverage comes from a single report by SiliconANGLE, which states that EliseAI raised $350 million, names Andreessen Horowitz and Bessemer as round leaders, gives the $4 billion valuation, and says the funds will go toward product expansion and hiring across engineering, deployment, and sales. Because only one article is provided, independent confirmation within the supplied coverage is limited.
- What remains uncertain
- The coverage does not specify the detailed terms of the round, revenue or customer traction metrics, or a timeline for product and hiring expansion. It also does not verify how quickly the new capital will translate into market share, product performance, or adoption outcomes in real estate and healthcare.
- Monitor next
- Watch for concrete follow-up signals such as announced product launches, major customer wins, or disclosed hiring and deployment expansion tied to this funding round.
Analytical support, not advice — assumptions and open questions stated above.